MedPath

cevimeline hydrochloride

Cevimeline Hydrochloride

Approved
Approval ID

efc2bb24-4dda-4781-bef5-fcd9abf082dd

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 5, 2023

Manufacturers
FDA

Cosette Pharmaceuticals, Inc.

DUNS: 116918230

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

cevimeline hydrochloride

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0713-0937
Application NumberNDA020989
Product Classification
M
Marketing Category
C73594
G
Generic Name
cevimeline hydrochloride
Product Specifications
Route of AdministrationORAL
Effective DateJanuary 5, 2023
FDA Product Classification

INGREDIENTS (4)

HYDROXYPROPYL CELLULOSE, UNSPECIFIEDInactive
Code: 9XZ8H6N6OH
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
CEVIMELINE HYDROCHLORIDEActive
Quantity: 30 mg in 1 1
Code: P81Q6V85NP
Classification: ACTIR

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

cevimeline hydrochloride - FDA Drug Approval Details